Odds of higher caries (DMFT) category · 12-year-old children across European countries (national/regional epidemiological surveys, 2011-2022)
Unemployment rate was not independently associated with DMFT category in the adjusted model (OR 0.99, 95% CI 0.44 to 2.23); not GRADE-rated.
1 finding from 1 review
Caries experience (mean DMFT) · Adults aged 19-60 years
Pooled caries experience (DMFT) was similar in very-high-HDI and high-HDI countries, and meta-regression found no significant association between national HDI and DMFT; ungraded observational evidence with very high heterogeneity.
3 findings from 1 review
Myocardial infarction · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (high dose) showed no clear difference in myocardial infarction compared with homocysteine‐lowering interventions (low dose) (moderate certainty).
1 finding from 1 review
Stroke · people with or without existing cardiovascular disease, men and women
It is very uncertain whether homocysteine‐lowering interventions (high dose) changes stroke compared with homocysteine‐lowering interventions (low dose) (very low certainty).
1 finding from 1 review
Death by any cause · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (high dose) showed no clear difference in death by any cause compared with homocysteine‐lowering interventions (low dose) (moderate certainty).
1 finding from 1 review
Cancer · people with or without existing cardiovascular disease, men and women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Leaving the study early · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. high dose (> 15‐35 mg/day) compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
2 findings from 1 review
Mortality, near term corrected age or discharge · preterm infants
Lower showed no clear difference in mortality, near term corrected age or discharge compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Neurodevelopmental disability · preterm infants
Lower showed no clear difference in neurodevelopmental disability compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Intubation in the delivery room · preterm infants
Lower showed no clear difference in intubation in the delivery room compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Severe (defined as stage 3 or greater) retinopathy of prematurity ‐ not reported · preterm infants
Lower showed no clear difference in severe retinopathy of prematurity (≥ stage 3) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review